Pyrazinamide Tablets IP 750 mg Manufacturer

Pyrazinamide Tablets IP 750 mg Manufacturer in India – Healthy Life Pharma Pvt. Ltd.

Pyrazinamide Tablets IP 750 mg Manufacturer product packaging

Pyrazinamide Tablets IP 750 mg | Manufacturer

Product image for Pyrazinamide Tablets IP 750 mg Manufacturer; contract manufacturing, oem & quality control.

Product Information

Generic NamePyrazinamide
ManufacturerHealthy Life Pharma Pvt. Ltd.
HSN Code30049053
PharmacopoeiaIP
Product TypeTablet
CategoryAntitubercular drugs
SubcategoryAntitubercular drugs
Active IngredientPyrazinamide
Strength750 mg
Dosage FormTablet
Pack Size10 x 10 Tablets / Box (Alu-Alu / Blister)
Route of AdministrationOral
Prescription RequiredYes
Therapeutic CategoryAntitubercular drugs

Medicine Details & Safety

Short DescriptionHealthy Life Pharma invites contract and third-party manufacturing enquiries for Pyrazinamide Tablets IP 750 mg from pharmaceutical marketing companies, institutional buyers and brand owners. Production specifications, batch size and packaging are agreed against the approved product dossier and purchase requirements.
Approved Uses / Indications1. First-line multidrug treatment of pulmonary and extrapulmonary tuberculosis. 2. Prophylaxis and latent tuberculosis infection management in high-risk individuals.
Full Description

Healthy Life Pharma invites contract and third-party manufacturing enquiries for Pyrazinamide Tablets IP 750 mg from pharmaceutical marketing companies, institutional buyers and brand owners. Production specifications, batch size and packaging are agreed against the approved product dossier and purchase requirements.

Product technical specifications

Generic namePyrazinamide
CompositionPyrazinamide
Strength750 mg
CategoryAntitubercular drugs
PharmacopoeiaIP
Dosage formTablet

Product technical specifications

Generic nameAcarbose
CompositionAcarbose
Strength25 mg
CategoryAntidiabetic Drugs
PharmacopoeiaUSP / IP
Dosage formTablet

Manufacturing capabilities and infrastructure

For Pyrazinamide Tablets IP 750 mg, assess the approved formulation process, equipment suitability, batch scale and in-process controls for the Tablet presentation. Confirm environmental requirements and validated process before production.

Quality control and assurance

Request the approved finished-product specification for Pyrazinamide Tablets IP 750 mg, including applicable identity, assay, uniformity and performance tests for the Tablet presentation. Confirm analytical methods, acceptance criteria and batch release documentation, including COA availability.

Primary and secondary packaging

The catalogue pack for Pyrazinamide Tablets IP 750 mg is 10 x 10 Tablets / Box (Alu-Alu / Blister). Confirm primary packaging compatibility, stability evidence, artwork, batch coding and leaflet requirements against the approved specification.

Contract manufacturing and private label

Submit the target market, strength, pharmacopoeial specification, forecast volume and brand artwork. Agree feasibility, batch size, quality agreement, production schedule and release criteria before execution.
Dosage InstructionsAdminister orally as a single daily dose on an empty stomach (at least 30 minutes before meals or 2 hours after meals) with water. Ensure continuous daily administration under directly observed therapy protocols.
Side EffectsCommon: Gastrointestinal distress, anorexia, nausea, orange-red discoloration of body fluids, mild transaminase rise. Uncommon: Peripheral neuropathy, arthralgia, headache, dizziness, cutaneous flushing. Rare: Drug-induced hepatotoxicity, optic neuritis, thrombocytopenia, hemolytic anemia.
Warnings and PrecautionsHepatic Function Surveillance: Baseline and monthly liver function tests are recommended; immediately discontinue if transaminases exceed 3-5 times normal. Neuropathy Prophylaxis: Co-administer pyridoxine (vitamin B6) in patients susceptible to peripheral neuritis. Adherence: Strict uninterrupted compliance is vital to prevent MDR-TB emergence.
Contraindications1. Hypersensitivity to Pyrazinamide or related hydrazide/rifamycin antimycobacterial drugs.
2. Severe acute liver disease or preexisting drug-induced hepatitis.
3. Severe peripheral neuropathy or preexisting optic neuritis (for ethambutol).
Drug Interactions1. Potent CYP Inducers/Substrates: Rifamycin derivatives accelerate hepatic metabolism of oral contraceptives, warfarin, and protease inhibitors.
2. Antacids: Aluminum hydroxide decreases antimycobacterial absorption; space dosing by 2 hours.
3. Hepatotoxic Drugs & Alcohol: Compounded risk of severe hepatic necrosis.

Frequently Asked Questions

QuestionAnswer
Can I request third-party manufacturing for Pyrazinamide Tablets IP 750 mg?Submit your brand, quantity and packaging requirements for manufacturing feasibility review.
Which pharmacopoeial standard applies for Pyrazinamide Tablets IP 750 mg?The source specification is IP; confirm the required standard before contracting.
What quality tests are applicable for Pyrazinamide Tablets IP 750 mg?Request the approved finished-product specification and batch testing plan.
Can packaging be customized for Pyrazinamide Tablets IP 750 mg?Submit artwork and pack requirements for technical and regulatory review.
How do I request a manufacturing quotation for Pyrazinamide Tablets IP 750 mg?Provide forecast volume, target market, strength and packaging requirements.

Product Tags

Pyrazinamide Tablets IP 750 mg ManufacturerPyrazinamide 750 mgContract ManufacturingOEM & Quality ControlHealthy Life Pharma Pvt. Ltd.

Product Hashtags

#Pyrazinamide#Manufacturer#PharmaB2B

Related Products

Latest Posts